Value Adjusted for Debt and Cash: Cara Corp (TVRD)

The Enterprise Value metric for Cara Therapeutics Inc (TVRD), currently at -5.05, serves as a key indicator for the biopharmaceutical business. While the company focuses on developing selective anti-pruritic agents for renal pathologies, it is currently facing a slowdown in the rollout of its approved product and failures in several studies. Nevertheless, the strategic success of Cara Therapeutics Inc (TVRD) is based on its unique drug, KORSUVA, which provides targeted symptom relief.

caratherapeutics.com (TVRD) - Total Company Value from 11/23/2025 to 11/01/2026

Cara Therapeutics Inc (TVRD) - metric breakdowns and financial figures

- stock price and consensus target price:

Price Chart Cara Therapeutics, Inc.|TVRD - Price Target Chart

- company stock exchange capitalization indicators:

Market Value Cara Therapeutics|TVRD - Enterprise Value

- book capitalization information:

Equity per Share Cara Therapeutics|TVRD - Company Book Value|Market Capitalization to Net Assets caratherapeutics.com|TVRD - Company Total Assets

- business debt structure and liquidity details:

- earnings and valuation multiples indicators:

TVRD - Net Income

Analysis of all company metrics:Cara Therapeutics, Inc.

Enterprise Value combines market capitalization and net debt, determining the actual cost of acquiring a business while accounting for all liabilities. For Cara Therapeutics Inc (TVRD), this metric is critical when evaluating patent value and synergies from partnerships with pharma behemoths; therefore, the historical Enterprise Value trend allows investors to assess the real price of assets without distortions from the debt load.

Competitors of Cara Therapeutics Inc (TVRD)